Tempus AI, Inc. - Class A Common Stock

Action · US88023B1035 · TEM (XNAS)

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur Tempus AI, Inc. - Class A Common Stock

Résumé de la Note des Analystes

Achat

Achat fort

Achat

Conserver

Vente

Vente forte

Pas de cours

29.04.2026 05:27

Cours actuels de Tempus AI, Inc. - Class A Common Stock

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
Quotrix	TAIIRS35.DUSD	EUR	29.04.2026 05:27	43,84 EUR	-1,04 EUR -2,33 %
NASDAQ	TEM	USD	28.04.2026 23:59	51,15 USD	-1,65 USD -3,12 %
IEX	TEM	USD	28.04.2026 19:59	51,12 USD	-1,68 USD -3,18 %
Düsseldorf	TAIIRS35.DUSB	EUR	28.04.2026 17:31	43,87 EUR	-1,02 EUR -2,26 %

Notation du Risque ESG

B Bon

Flottant et Liquidité des Actions

Flottant Libre 60,27 %

Actions en Flottant 105,09 M

Actions en Circulation 174,36 M

Profil de l'entreprise pour Tempus AI, Inc. - Class A Common Stock Action

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.